(via TheNewswire)

Toronto, Ontario – TheNewswire - 16 March, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, today reported financial results and the filing of the Company’s unaudited interim financial statements as of and for the three- and six-month periods ended January 31, 2026 (the “Financial Statements” ), the management’s discussion and analysis ( “MD&A” ), and the certifications of the Chief Executive Officer and Chief Financial Officer (respectively, “CEO” and “CFO” ) relating to the Financial Statements (collectively, the “Interim Filings” ). All values are in Canadian dollars unless stated otherwise.

“While our current financial position reflects a challenging capital markets environment for small-cap biotech companies, our focus remains firmly on securing the financing necessary to advance Helix into its next phase,” said Thomas Mehrling, MD, PhD, Chief Executive Officer of the Company. “The Management and Board are actively pursuing financing opportunities aimed at securing approximately twelve months of operating runway, which will allow the Company to pursue its near-term objectives, including listing on a U.S. securities exchange. While there is still work to be done, we have reason to be cautiously optimistic as we intensify these efforts and expect to communicate further on our roadmap to achieve this goal soon.”

Financial Highlights:

• The Company incurred a net and total comprehensive loss from operations of $694,000 for the three months ended January 31, 2026, and a loss of $1,702,000 for the six months ended January 31, 2026, versus a net loss of $1,375,000 and $2,711,000 for the three and six months ended January 31, 2025, respectively. The decrease in net loss was primarily due to the closing out of the Company’s LDOS006 clinical trial in metastatic pancreatic adenocarcinoma and reduced research activities, partially offset by an increase in operating, general and administrative expenses associated with accounting, tax, legal, and consulting fees.  

• The net and total comprehensive loss for the reporting period corresponds to a loss of $0.01 and $0.05 per common share for the three and six months ended January 31, 2026, respectively, versus a loss of $0.03 and $0.02 per common share for the three and six months ended January 31, 2025, respectively.  

• The Company had cash of $31,000 as of January 31, 2026, down from $1,996,000 at the end of the three months ended January 31, 2025. The Company anticipates that existing cash reserves are insufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months, nor are they sufficient to see the current research and development activities through to completion.  

• On December 5, 2025, the Company entered into a subscription agreement with Quantum Global Ventures AG for the purchase of 18,538,889 common shares at $1.80 per share, for extended gross proceeds of $33,370,000. The subscription agreement was fully executed by both parties. However, subsequent to the reporting period, Quantum Global Ventures AG declared bankruptcy and the Company did not receive any of the subscription proceeds. As a result, the financing did not close.  

• Following the end of the reporting period, the Company signed a term sheet with Alumni Capital Limited in respect of a potential financing transaction. Consistent with the Company’s confidentiality obligations, the specific commercial terms of the term sheet and potential transaction are not disclosed.  

The Interim Filings

For more information, please see the Interim Filings, which are available on the Company’s profile at www.sedarplus.ca and on its website at https://www.helixbiopharma.com/filings-and-financials/ .  

About Helix BioPharma

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA™, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0). For more information, please visit : https://www.helixbiopharma.com/

For more information, please contact:

Helix BioPharma Corp.

Bay Adelaide Centre - North Tower

40 Temperance Street, Suite 2700

Toronto, ON M5H 0B4

Tel: +1 857 208 7687

Jacek Antas, Director

corporate@helixbiopharma.com

Forward-Looking Statements and Risks and Uncertainties

This news release contains forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company’s future business, operations, research and development, including the Company’s activities relating to DOS47, LR 09 and GEMCEDA. Forward-looking statements can further be identified by the use of forward-looking terminology such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.

Forward-looking statements are necessarily based on a number of estimates and assumptions that the Company considered appropriate and reasonable as of the date such information is given, including but not limited to the assumptions regarding the implied benefits of the transactions. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, including but not limited to the risk that the Company's assumptions on which its forward-looking statements are based may not be accurate; the ability of the Company to capitalize on the potential benefits of the transactions; and the risk factors disclosed in the Company's periodic reports publicly filed and available on its SEDAR+ profile at  www.sedarplus.ca . No assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur. There is no assurance that the proposed transactions will be completed in accordance with its terms or at all. The forward-looking statements contained in this news release are made as of the date of this announcement and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.

_________________

Copyright (c) 2026 TheNewswire - All rights reserved.